[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Holsinger FC, Kies MS, Diaz EM Jr, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR: Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol; 2009 Apr 20;27(12):1976-82
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
  • PURPOSE: For patients with stage II to IV laryngeal cancer, radiation therapy (RT) either alone or with concurrent chemotherapy provides the highest rate of organ preservation but can be associated with functional impairment.
  • Thus, we studied the use of induction chemotherapy with or without conservation laryngeal surgery (CLS).
  • Our objectives were to study the sensitivity of laryngeal cancer to platinum-based chemotherapy alone and to highlight the efficacy of CLS in this setting.
  • PATIENTS AND METHODS: Thirty-one previously untreated patients with laryngeal cancer (T2-4, N0-1, M0), who were resectable with CLS, were enrolled.
  • Patients received three to four cycles of paclitaxel, ifosfamide, and cisplatin (TIP) chemotherapy, and response was assessed histologically.
  • Patients achieving pathologic complete response (pCR) received an additional three cycles of TIP and no other treatment.
  • With TIP chemotherapy alone, 11 patients (37%) achieved pCR, 10 of whom (33%) remain alive with durable disease remission and no evidence of recurrence over a median follow-up time of 5 years.
  • The overall laryngeal preservation (LP) rate was 83%, and only five patients (16%) required postoperative RT.
  • CONCLUSION: Chemotherapy alone in selected patients with T2-4, N0-1 laryngeal cancer can provide durable disease remission at 5 years.
  • This prospective study suggests that chemotherapy alone may cure selected patients with laryngeal cancer, warranting further prospective investigation.

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1096-104 [11181674.001]
  • [Cites] Head Neck. 2008 Feb;30(2):148-58 [17786992.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1316-23 [11283932.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Head Neck. 2002 May;24(5):456-67 [12001076.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):322-30 [12124833.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Cancer. 2004 May 1;100(9):1786-92 [15112257.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):577-84 [1898708.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1325-30 [9552033.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1331-9 [9552034.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):40-6 [9921972.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1387-94 [16115737.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • [Cites] Head Neck. 2006 Jan;28(1):64-73 [16302193.001]
  • [Cites] Science. 2006 May 26;312(5777):1162-5 [16728627.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Head Neck. 2006 Sep;28(9):779-84 [16637055.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S129-31 [17848281.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):178-83 [18283161.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):170-5 [18377831.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3582-9 [18559875.001]
  • [CommentIn] J Clin Oncol. 2009 Apr 20;27(12):1933-4 [19289612.001]
  • (PMID = 19289628.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / P50CA97007; United States / NCI NIH HHS / CA / K12 CA088084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ PMC2738635
  •  go-up   go-down


2. Liu WS, Hsin CH, Chou YH, Liu JT, Wu MF, Tseng SW, Lee JK, Tseng HC, Wang TH, Su MC, Lee H: Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation. BMC Cancer; 2010;10:102
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
  • BACKGROUND: The objective of this retrospective study is to investigate laryngeal preservation and long-term treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined with chemotherapy.
  • METHODS: Twenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent concurrent chemoradiotherapy.
  • The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six patients and weekly cisplatin for 19 patients.
  • RESULTS: The median follow-up time for survivors was 53.0 months (range 36-82 months).
  • The initial complete response rate was 85.2%, with a laryngeal preservation rate of 63.0%.
  • The 5-year functional laryngeal, local-regional control, disease-free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively.
  • The most common greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal stricture (18.5%, 5 of 27 patients), respectively.
  • CONCLUSIONS: After long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-regional control survival rates.
  • However, the late effect of laryngeal stricture remains a problem, particularly for high risk group patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Larynx / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Radiotherapy, Intensity-Modulated / adverse effects. Radiotherapy, Intensity-Modulated / methods. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):195-205 [10656393.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21 [16168834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):65-71 [10758306.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Cancer. 2001 Apr 20;96(2):126-31 [11291096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Laryngoscope. 1977 Aug;87(8):1288-303 [881922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):357-63 [6423584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Cancer J. 2006 Nov-Dec;12(6):494-500 [17207319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):36-41 [17709149.001]
  • [Cites] Auris Nasus Larynx. 2007 Dec;34(4):499-504 [17604583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85 [18164838.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] Acta Otolaryngol. 2009 Mar;129(3):311-7 [18607975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):146-53 [19553034.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Head Neck. 2005 Jan;27(1):15-21 [15515158.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 May;262(5):374-8 [15906056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30 [10701741.001]
  • (PMID = 20298550.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3087314
  •  go-up   go-down


3. Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N: [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study]. Acta Otorrinolaringol Esp; 2003 Dec;54(10):697-703
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
  • [Transliterated title] Quimioterapia de inducción con vinorelbine, cisplatino y UFT en carcinomas avanzados faringo-laríngeos: resultados de un estudio fase II.
  • OBJECTIVE: To evaluate the results of an induction chemotherapy protocol with Vinorelbine, UFT and Cisplatin (UFTVP).
  • METHODS: 93 patients with laryngo-pharyngeal squamous cell carcinoma in stage III or IV were prospectively entered into a protocol to receive four cycles of UFTVP.
  • Responders followed definitive radiation therapy.
  • RESULTS: Following chemotherapy nodal response (complete in 28% and partial in 33%) was less than that the primary site (complete in 60% and partial in 30%), p = 0.002.
  • Successful larynx preservation was achieved in 50% of patients with laryngeal cancer and in 29% of patients with hypopharyngeal cancer.
  • CONCLUSIONS: UFTVP is an active regime of chemotherapy in advanced squamous cell carcinoma of the pharynx and larynx.
  • Results differ according to the localization, having significantly better rates of survival and organ preservation in the laryngeal cancers that in those of the pharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngectomy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Prospective Studies. Remission Induction. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15164709.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; 1-UFT protocol
  •  go-up   go-down


Advertisement
4. Mantz CA, Vokes EE, Kies MS, Mittal B, Witt ME, List MA, Weichselbaum RR, Haraf DJ: Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol; 2001 Mar;12(3):343-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer.
  • PURPOSE: To determine overall survival, progression-free survival, rate of voice preservation, and patterns of failure in locoregionally advanced laryngeal cancer treated with induction chemotherapy with or without surgery followed by concomitant chemoradiation.
  • BACKGROUND: Locoregionally advanced laryngeal cancer has been conventionally treated with either surgery and adjuvant radiotherapy or radiotherapy alone, and clinical and functional outcomes have been poor.
  • Chemoradiotherapy has been demonstrated to improve functional outcome and disease control over conventional treatment in recent randomized head and neck trials.
  • PATIENTS AND METHODS: Advanced head and neck cancer patients were enrolled onto two consecutive phase II studies.
  • Induction treatment consisted of three cycles of cisplatin, 5-fluorouracil (5-FU), leucovorin, and interferon-alpha 2b (PFL-IFN) followed by surgery for residual disease.
  • Surgical intent was to spare the larynx when possible.
  • RESULTS: A subset of thirty-two laryngeal cancer patients with predominantly stage IV disease comprises the study group for this report.
  • Clinical CR was observed in 59% of patients following induction therapy.
  • Only two total laryngectomies were performed during the course of treatment and follow-up.
  • Treatment-related toxicity accounted for two deaths.
  • CONCLUSIONS: The addition of concomitant chemoradiotherapy to induction chemotherapy for locoregionally advanced laryngeal cancer appears to increase locoregional control and survival rates.

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332146.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Worden FP, Moyer J, Lee JS, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Hogikyan N, Lassig AA, Emerick K, Mukherji S, Hadjiski L, Tsien CI, Miller TH, Wallace NE, Mason HL, Bradford CR, Wolf GT: Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope; 2009 Aug;119(8):1510-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
  • OBJECTIVES/HYPOTHESIS: High rates of overall survival (OS) and laryngeal preservation were achieved in two sequential phase II clinical trials in patients with stage III/IV laryngeal squamous cell carcinoma (SCC).
  • Patients were treated with chemoradiation after a >50% primary tumor response to one cycle of neoadjuvant chemotherapy (IC).
  • METHODS: Records from 36 patients with T4 SCC of the larynx with cartilage invasion alone (n = 16) or cartilage invasion and extralaryngeal spread (n = 20) were retrospectively reviewed.
  • Those achieving >50% response at the primary tumor received chemoradiation (70 Gy; 35 fractions with concurrent cisplatin-100 mg/m(2) [carboplatin (AUC 6)] every 21 days for 3 cycles), followed by adjuvant P+5FU for complete histologic responders (CHR).
  • Of these, 27 received definitive chemoradiation, 23 (85%) obtained CHR, with 58% laryngeal preservation rate.
  • Following chemoradiation, 8/11 (73%) patients with an intact larynx had >75% understandable speech, 6/36 (17%) were g-tube dependent and 6/36 (17%) were tracheostomy dependent.
  • CONCLUSIONS: Our results suggest that chemo-selection is a feasible organ preservation alternative to total laryngectomy for patients with T4 laryngeal SCC with cartilage invasion.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1478-85 [11720432.001]
  • [Cites] Head Neck. 2002 May;24(5):456-67 [12001076.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):467-72 [6486314.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):564-9 [2364368.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):559-68 [9635702.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):830-5 [16564646.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):655-61 [16785412.001]
  • [Cites] Curr Opin Oncol. 2007 May;19(3):188-94 [17414635.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 19504552.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE013346-05; United States / NCI NIH HHS / CA / P50 CA097248-05; United States / NCI NIH HHS / CA / P50 CA97248; United States / NIDCD NIH HHS / DC / P30 DC 05188; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NIDCD NIH HHS / DC / DC005188-07; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NCI NIH HHS / CA / CA097248-05; United States / NIDCD NIH HHS / DC / P30 DC005188-07; United States / NIDCR NIH HHS / DE / DE013346-05; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS126278; NLM/ PMC2739984
  •  go-up   go-down


6. Ishii K, Tashiro M, Hosono M, Fukuda H, Takada Y, Kondo S, Inoue Y, Iguchi H, Kusuki M, Yamane H: Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer. Acta Otolaryngol Suppl; 2004 Oct;(554):62-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
  • OBJECTIVE: This study was conducted to evaluate the efficacy and feasibility of our accelerated hyperfractionation with concomitant boost for stage II laryngeal cancer and stages III-IVb locally advanced head and neck cancer.
  • PATIENTS AND METHODS: From January 2000 to October 2001, eight patients with AJCC 1998 stage II laryngeal cancer and 11 patients with AJCC 1998 stages III-IVb locally advanced head and neck cancer underwent accelerated hyperfractionated radiation therapy.
  • For the stage II laryngeal cancer, radiation was delivered at a 2.0 Gy fraction a day, 5 fractions per week for the first 3 weeks, then 2 fractions (1.8 and 1.2 Gy) a day, 5 times a week for 2.5 weeks, with total dose of 69 Gy.
  • For stages III-IVb head and neck cancer, radiation was given at a 1.8 Gy fraction a day, 5 fractions per week for 6 weeks and a boost was added up to 70.5 Gy with 1.5 Gy as a second daily fraction during the last 2.2 weeks.
  • Among the patients, 16 (84%) received concomitant chemotherapy, mainly with low-dose carboplatin.
  • Acute toxicity based on RTOG criteria and tumor response at 1 month post-treatment were estimated as initial effects.
  • RESULTS: The overall response rate was 100% in patients with stage II laryngeal cancer and 91% in patients with stages III and IVb head and neck cancer.
  • Eighteen patients (95%) completed radiation therapy without interruption related to acute side effects, while one had prolongation of the treatment for more than 1 week because of neutropenia.
  • CONCLUSIONS: Our results demonstrated that accelerated hyperfractionation, mostly combined with concomitant chemotherapy, had a good overall response rate with acceptable toxicity in stage II laryngeal cancers and stages III-IVb head and neck tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Head and Neck Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15513514.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


7. Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, De Waziers I: Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer; 2001 Sep 1;93(5):725-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
  • Glutathione S-transferases (GSTs) are metabolic phase II enzymes that promote reactive metabolite elimination by conjugating them to glutathione (GSH).
  • Moreover, their influence on response to chemotherapy in cancer patients has been demonstrated.
  • To investigate the role of GST enzymes in carcinogenesis and in response to chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC), GSTP1, GSTM1 and GSTT1 were studied prospectively in a large series of HNSCC patients.
  • Correlations between GST alterations, p53 mutation status and clinical response to chemotherapy were investigated.
  • We showed that the risk of developing laryngeal cancer was increased by 2.6-fold [95% CI 1.6--6.1] in patients with the GSTM1 null genotype and by 2.8-fold [95% CI 0.9--8.1] in patients with the homozygous GSTP1 val105 genotype.
  • Two types of multivariate analysis were performed including parameters that have been shown to influence response to chemotherapy significantly in univariate analysis. p53 mutations and high tumor stage are independent factors of non-response to chemotherapy, whereas plasmatic GSTP1 levels and low tumor stage are independent factors of complete response.
  • Our data suggest that GST enzymes are associated with larynx cancer and that their use as predictive factors and treatment targets should be further explored.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Glutathione Transferase / blood. Head and Neck Neoplasms / enzymology. Isoenzymes / blood
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Gene Frequency. Genotype. Glutathione S-Transferase pi. Humans. Male. Middle Aged. Multivariate Analysis. Mutation. Neoadjuvant Therapy. Treatment Outcome. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11477586.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Isoenzymes; 0 / Tumor Suppressor Protein p53; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N, Taylor J: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol; 2006 Feb 1;24(4):593-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.
  • PURPOSE: Primary chemoradiotherapy in patients with advanced laryngeal cancer can achieve high rates of organ preservation without sacrificing survival compared with radiation alone or conventional laryngectomy.
  • Appropriate selection of patients for organ preservation approaches could enhance overall treatment outcome and quality of life.
  • We conducted a phase II organ preservation trial for patients with stage III and IV larynx cancer to determine whether late salvage surgery rates could be decreased and survival improved by selecting patients for organ preservation based on response to a single cycle of induction chemotherapy.
  • PATIENTS AND METHODS: The chemotherapy was cisplatin 100 mg/m2 on day 1 and fluorouracil 1,000 mg/m(2)/d for 5 days.
  • Histologic complete responders after chemoradiotherapy received two more cycles of chemotherapy.
  • A total of 29 patients (30%) had salvage surgery; 19 patients (20%) had early salvage surgery after the single cycle of induction chemotherapy, three patients (3%) had late salvage surgery after chemoradiotherapy, six patients (6%) eventually had salvage surgery for recurrence, and one patient had laryngectomy for chondroradionecrosis.
  • The median follow-up time was 41.9 months.
  • Larynx preservation was achieved in 69 patients (70%).
  • CONCLUSION: These results confirm excellent larynx preservation and improved overall survival rates compared with historical results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy / methods. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Lymphatic Metastasis. Male. Middle Aged. Necrosis. Neoplasm Staging. Quality of Life. Radiotherapy, Adjuvant / adverse effects. Remission Induction. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Feb 1;24(4):540-3 [16380409.001]
  • (PMID = 16380415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA/DE97248
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L, Mudu MC, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Tore G, Mura M, Amichetti M, Maccio A: Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol; 2002 Feb;20(2):419-27
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
  • The purpose of the study was to assess response rate, clinical outcome, organ/function preservation and toxicity in head and neck cancer patients treated with induction chemotherapy followed by concomitant chemoradiotherapy and, when necessary, limited surgery.
  • The study design was a phase II non-randomized trial in hospitalized patients setting.
  • The treatment plan consisted of 3 cycles of induction chemotherapy with cisplatin, fluorouracil (5-FU), l-leucovorin and interferon alpha2b (PFL-IFN) followed by 7 cycles of 5-FU, hydroxyurea and concomitant radiation for 5 days (FHX) for a total radiation dose of 70 Gy.
  • 13 Cis-retinoic acid was added to treatment regimen for chemoprevention and a systematic prophylaxis of mucositis was administered to all patients during FHX.
  • Conservative surgical resection was reserved to patients with no optimal response (PR > or =70%), whereas radical surgery was performed as salvage treatment.
  • Twenty-six patients were treated at one institution: more than 90% had stage IV disease and only 19.2% had laryngeal cancer.
  • Eighty-one percent of patients had performance status 0 and 23.1% of patients had >5% weight loss at the start of treatment.
  • At the completion of FHX, no patient underwent local therapy according to treatment plan.
  • At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
  • The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
  • In the present study, the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
  • In conclusion, this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic; moreover, the long overall treatment duration must be taken into consideration.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Cytokines / metabolism. Dose-Response Relationship, Radiation. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Inflammation / chemically induced. Inflammation / metabolism. Interferon-alpha / adverse effects. Interferon-alpha / therapeutic use. Leptin / metabolism. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Quality of Life. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11788911.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon-alpha; 0 / Leptin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Dietz A, Nollert J, Eckel H, Volling P, Schröder M, Staar S, Conradt C, Helmke B, Dollner R, Müller RP, Wannenmacher M, Weidauer H, Rudat V: [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study]. HNO; 2002 Feb;50(2):146-54
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study].
  • [Transliterated title] Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie. Ergebnisse einer multizentrischen Phase-II-Studie.
  • INTRODUCTION: Regarding the promising results of international trials we conducted the first German prospective multicentre phase II trial for organ preservation with primary simultaneous chemoradiation in advanced laryngeal and hypopharyngeal cancer.
  • PATIENTS AND METHODS: 28 of 30 recruited patients suffering from stage II and III (UICC) laryngeal and hypopharyngeal cancer were treated with primary simultaneous chemoradiation within an organ preservation program and monitored in follow-up of one year.
  • Exclusion criteria included tumor infiltration of the laryngeal cartilage, bilateral neck nodes (N2c) and need for flap reconstruction in case of laryngectomy.
  • The protocol included an accelerated concomitant boost chemoradiation (66 Gy) with Carboplatinum (70 mg/m2 1st and 5th week) and a restaging procedure one month after therapy.
  • RESULTS: After follow-up of one year 20 of 28 patients (71%) were presented with stable complete remission and functionally preserved larynx.
  • Of these 20 patients 3 developed pulmonary metastases, 1 secondary primary carcinoma of the lung and 3 neck metastases which needed neck dissections.
  • Further studies should focus on the improvement of patient selection which could be realized by induction Chemotherapy (using new components like taxan) and/or use of prediction factors such as tumor volume and hemoglobin levels.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] HNO. 2002 Feb;50(2):109-13 [12080620.001]
  • (PMID = 12080625.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Yoon TM, Lee JK, Cho JS, Lim SC, Chung WK: Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer. J Otolaryngol Head Neck Surg; 2010 Apr;39(2):142-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer.
  • OBJECTIVES: The efficacy and toxicity of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy or radiotherapy only and their impact on laryngeal preservation and survival were studied in patients with supraglottic cancer.
  • METHODS: Forty-four patients with newly diagnosed supraglottic squamous cell carcinoma (stage II, III, IV) were treated with either two to three cycles of neoadjuvant chemotherapy with cisplatin 100 mg/m2 on day 1 and fluorouracil 800 to 1000 mg/m2 on days 1 to 5, followed by radiotherapy (NC + RT group, from March 1995 to December 1999; median 68.7 Gy, 1.8 to 2 Gy per fraction) or concurrent chemoradiotherapy (NC + CCRT group, from January 2000 to February 2003; radiotherapy concurrently with cisplatin 60 to 80 mg/m2 on day 1 and fluorouracil 600 to 800 mg/m2 on days 1 to 5).
  • Age, nodal stage, and tumour response after neoadjuvant chemotherapy were significant prognostic factors for OS and DSS (p < .05).
  • The 5-year disease-specific survival rates with larynx preservation were 42% in the NC + RT group and 73% in the NC + CCRT group (p = .028).
  • CONCLUSIONS: Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with cisplatin and fluorouracil was effective as primary therapy for supraglottic cancer with laryngeal preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Supraglottic laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211100.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Dragnev KH, Petty WJ, Memoli V, Black W, Williams I, Rigas JR, Dmitrovsky E: A phase I/II study of bexarotene (B) and erlotinib (E): A novel targeted combination therapy for lung cancer and other aerodigestive tract (ADT) tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):3092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of bexarotene (B) and erlotinib (E): A novel targeted combination therapy for lung cancer and other aerodigestive tract (ADT) tumors.
  • Treatment of BEAS-2B human bronchial epithelial cells (HBEC) with tobacco carcinogens enhanced cyclin D1 and epidermal growth factor receptor (EGFR) expression.
  • Similar effects were noted with the rexinoid (B), bypassing the need for intact RAR-β signaling often deregulated in lung cancer.
  • METHODS: Phase I/II trial of B and E in advanced ADT tumors.
  • RESULTS: Eight pts were enrolled, accrual continues -stage IV NSCLC (6), laryngeal (1), salivary gland (1).
  • 7 patients had prior chemotherapy.
  • CONCLUSIONS: Preliminary results indicate this is a well-tolerated regimen with activity in lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lefebvre JL, Chevalier D, Luboinski B, Traissac L, Andry G, De Raucourt D, Collette L, Bernier J, EORTC Head and Neck Cancer Cooperative Group: Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):5531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial.
  • : 5531 Background: In 1986, the EORTC HNCCG initiated a randomized phase III trial to assess whether LP using ICT followed by radiation therapy (XRT) was as safe as the conventional treatment: total laryngectomy with partial pharyngectomy (TLP), radical neck dissection (RND) and postop XRT.
  • METHODS: 202 patients (pts) candidates for TLP + RND + XRT were randomly assigned to receive in the surgery arm (arm 1) this treatment or in the ICT arm (arm 2) up to 3 cycles of CDDP (100mg/m<sup>2</sup> day 1) and 5FU (1000 mg/m<sup>2</sup> days 1-5) followed in case of complete response by XRT or by TPL + RND + XRT in the other cases.
  • The endpoints were survival (OS and PFS) and LP defined as a functional larynx free of disease (larynx in place without tracheotomy, feeding tube or gastrostomy, and without evidence of local disease).
  • Stage II, III and IV respectively numbered 6, 51 and 37 in arm 1 and 7, 59 and 34 in arm 2.
  • In arm 2 survival with a functional larynx in place was 22 % at 5 years and 9 % at 10 years.
  • This LP strategy provided similar survival curves as compared with conventional treatment and allowed 2/3 of the survivors to retain their larynx.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lau H, Yee D, Mackinnon J, Brar S, Hao D, Gluck S: Concomitant low-dose cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Analysis of survival and toxicity. J Clin Oncol; 2004 Jul 15;22(14_suppl):5555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant low-dose cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Analysis of survival and toxicity.
  • METHODS: From July 2000 to April 2003, 57 patients with locally advanced SCCHN were treated with a regimen of 3D conformal RT, 70 Gy over 7 weeks with concurrent cisplatin 20 mg/M<sup>2</sup> during days 1 - 4 of weeks one and five.
  • Eligible patients included stage II oropharyngeal (4), stage III (12), and stage IV (34) oropharyngeal, hypopharyngeal, and laryngeal SCC cancers.
  • Patients were evaluated by surgeon, radiation oncologist, and medical oncologist prior to treatment.
  • Acute toxicities were graded weekly during treatment and in follow-up according to the RTOG / CTC toxicity criteria.
  • All completed the prescribed radiation dose of 70 Gy.
  • Chemotherapy compliance was as follows: 31 patients (54%) completed 100% of chemotherapy and the remainder completed >= 50% of chemotherapy.
  • Treatment Toxicity: 27/57 (47%) of patients required hospitalization during treatment for supportive care.
  • CONCLUSIONS: This regimen appears tolerable and adds minimal excess toxicity compared to treatment with radiation alone.
  • Our results are comparable to concurrent chemotherapy regimens using either high-dose cisplatin or multiagent chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nagatani G, Mori T, Udaka T, Shiomori T, Ohbuchi T, Suzuki H: [Clinical study of early laryngeal cancer]. Nihon Jibiinkoka Gakkai Kaiho; 2007 Jun;110(6):447-52
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of early laryngeal cancer].
  • We retrospectively analyzed 71 consecutive cases of early laryngeal cancer (stage I or II) that had undergone primary treatment in our department between 1999 and 2004.
  • Eight patients had the supraglottic type, 61 had the glottic type, and 2 had the subglottic type.
  • Chemoradiotherapy was performed as the primary treatment except in the patients with glottic T1a cancer, who received radiotherapy alone.
  • The 5-year survival rates was 91.1% for glottic cancer (T1a: 100%, T1b: 92.3%, T2: 85.8%) and 75.0% for supraglottic cancer.
  • The local control rate of glottic cancer was 79.6% (T1a: 80.0%, T1b: 74.0%, T2: 85.2%), and significantly higher than that of supraglottic cancer (56.2%, p < 0.05).
  • The laryngeal preservation rate was 84.4% in glottic cancer (T1a: 100%, T1b: 76.9%, T2: 77.5%) and 58.3% in supraglottic cancer, and the difference between T1a and T2 glottic cancer was significant (p < 0.05).
  • Distant metastasis occurred in 4 patients, all of whom had the glottic type.
  • These results indicate that additional treatment should be performed in cases in which radiotherapy/chemoradiotherapy is ineffective and that both in the early stages glottic and supraglottic cancers can be successfully treated by radiotherapy/chemoradiotherapy.
  • The results also suggested that the survival of patients with early laryngeal cancer depends on whether they develop distant metastasis.
  • Introduction of adjuvant chemotherapy to improve their prognosis remains to be assessed.
  • [MeSH-major] Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633113.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Morimoto M, Takemura H, Yui T, Suzuki T, Sanbe T, Suzaki H: [Efficacy of concomitant therapy with S-1, CDGP, and radiation for laryngeal cancer]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1903-6
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of concomitant therapy with S-1, CDGP, and radiation for laryngeal cancer].
  • OBJECTIVE: Several clinical trials examining treatment strategies for advanced laryngeal cancer have demonstrated that concurrent chemoradiotherapy is the most effective treatment for improving the patient response to radiotherapy and laryngeal preservation.
  • We evaluated a new regimen of S-1/CDGP(Nedaplatin) with radiotherapy (RT), and established that it represented an effective new treatment option that allowed for the preservation of the larynx.
  • METHODS: A total of 16 patients with stage II to IV laryngeal cancer(excluding T4 stage)who had been treated at our institution from 2001 to 2007 were recruited for the present study.
  • RESULTS: The administration of S-1/CDGP/RT led to a complete response (CCR) in all patients with stage II or IV disease, with preservation of the larynx in all of these cases.
  • For patients with stage III disease, 6 (85%) experienced CR, and 1 patient (15%) had a partial response.
  • The laryngeal preservation rate for these patients was 85%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948253.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


17. Fung K, Lyden TH, Lee J, Urba SG, Worden F, Eisbruch A, Tsien C, Bradford CR, Chepeha DB, Hogikyan ND, Prince ME, Teknos TN, Wolf GT: Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys; 2005 Dec 1;63(5):1395-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.
  • INTRODUCTION: Organ-preservation treatment approaches for advanced laryngeal cancer patients that use combination chemoradiotherapy result in cure rates similar to primary laryngectomy with postoperative radiotherapy.
  • In the national VA Larynx Cancer Trial, successful organ preservation was associated with an overall improvement in quality of life but not in subjective speech compared with long-term laryngectomy survivors.
  • As part of a Phase II clinical trial, a prospective study of speech and swallowing results was conducted to determine if larynx preservation is associated with improved voice and swallowing compared with results in patients who require salvage laryngectomy.
  • SUBJECTS: A total of 97 patients with advanced laryngeal cancer (46 Stage III, 51 Stage IV) were given a single course of induction chemotherapy (cisplatin 100 mg/m2 on Day 1 and 5-FU 1,000 mg/m2/day x 5 days), followed by assessment of response.
  • Patients with less than 50% response underwent early salvage laryngectomy, and patients with 50% or better response underwent concurrent chemoradiation (72 Gy and cisplatin 100 mg/m2 on Days 1, 22, and 43), followed by two cycles of adjuvant chemotherapy (DDP/5-FU).
  • Direct laryngoscopy and biopsy were performed 8 weeks after radiation therapy to determine final tumor response.
  • METHODS: Completed survey data on voice and swallowing utilizing the Voice-Related Quality of Life Measure (V-RQOL) and the List Performance Status Scale for Head and Neck Cancer Patients (PSS-HN) were obtained from 56 patients who were alive and free of disease at the time of survey, with a minimum follow-up of 8 months.
  • Comparisons were made between patients with an intact larynx (n = 37) vs. laryngectomy (n = 19), as well as early (n = 12) vs. late salvage laryngectomy (n = 7).
  • RESULTS: Patients with an intact larynx demonstrated significantly higher (p = 0.02) mean V-RQOL scores (80.3) than did laryngectomy patients (65.4).
  • Multiple linear regression revealed that predictors of higher total V-RQOL scores include lower T stage (p = 0.03), organ preservation (p = 0.0007), and longer duration since treatment (p = 0.01).
  • Understandability of speech was better in patients with an intact larynx (p = 0.001).
  • Multiple logistic regression revealed that longer duration since treatment (p = 0.03, odds ratio = 1.1) and lower maximal mucositis grade (p = 0.03, odds ratio = 0.3) were predictive of higher likelihood of eating in public.
  • Nutritional mode consisting of oral intake alone without nutritional supplements was achieved in 88.9% of patients with an intact larynx compared with 64.3% of laryngectomees (p = 0.09).
  • CONCLUSIONS: Voice-related quality of life is better in patients after chemoradiation therapy compared with salvage laryngectomy.
  • Overall swallowing function is good in all patients; however, patients with an intact larynx are more likely to obtain nutrition with oral intake alone without supplements.
  • Such measures of function and quality of life are important endpoints to help judge overall effectiveness as newer, more aggressive treatment protocols with added toxicities are developed and evaluated.
  • [MeSH-major] Deglutition. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Quality of Life. Voice Quality
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Speech Intelligibility

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087298.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Tian WD, Zeng ZY, Chen FJ, Wu GH, Guo ZM, Zhang Q: [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma]. Ai Zheng; 2006 Jan;25(1):80-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma].
  • BACKGROUND & OBJECTIVE: Laryngeal squamous cell carcinoma (LSCC) is a common malignancy of the head and neck.
  • Stage I-II LSCC patients have a favorable prognosis after operation or radiotherapy, but the curative effect and prognosis of stage III-IV LSCC are not satisfying, and its treatment is also controversial.
  • This study was to summarize our experience in treating stage III-IV LSCC patients, evaluate the treatment results, and seek more reasonable therapeutic modality.
  • METHODS: Records of 202 stage III-IV LSCC patients, treated in Cancer Center of Sun Yat-sen University from Jan.
  • Of the 202 patients, 64 received surgery alone, 83 received surgery and preoperative or postoperative radiotherapy, 41 received radiotherapy, and 14 received chemotherapy.
  • RESULTS: The 5- and 10-year overall survival rates of the 202 patients was (42.12+/-3.62)% and (33.20+/-4.32)%, and the median survival time was 48.5 months.
  • The 5-year survival rates were 61.07% in glottic carcinoma group and 26.07% in supraglottic carcinoma group, and were 53.41% in surgery alone group, 51.04% in surgery plus radiotherapy group, 18.33% in radiotherapy group and 7.14% in chemotherapy group.
  • CONCLUSIONS: Surgery, especially total laryngectomy, is the major treatment modality for stage III-IV LSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery. Laryngectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405756.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Stiles BM, Mirza F, Port JL, Lee PC, Paul S, Christos P, Altorki NK: Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer. Ann Thorac Surg; 2010 Dec;90(6):1805-11; discussion 1811
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer.
  • BACKGROUND: Although patients with esophageal cancer (EC) often develop lymph node metastases in the cervical and recurrent laryngeal (CRL) distribution, lymphadenectomy in this field is rarely performed.
  • Final pathology stages (seventh edition) were I in 24 patients, II in 43, III in 109, and IV in 1 patient.
  • Eight patients had a major pathologic response after induction therapy.
  • There was no reduction in the rate of positive CRL nodes after induction chemotherapy.
  • CONCLUSIONS: Complete lymphadenectomy is necessary in esophageal cancer to appropriately stage patients.
  • Low rates of positive CRL nodes are present with early clinical stage, with pT0-2 tumors, and with pN0 classification, particularly in patients with adenocarcinoma and gastroesophageal junction tumors.
  • Dissection of the CRL field should be considered with advanced disease for adenocarcinoma and in all patients with squamous cell cancer.
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Larynx. Male. Neck. Neoplasm Staging. New York / epidemiology. Odds Ratio. Prognosis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 21095315.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1-RR024996
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Cmelak AJ, Li S, Goldwasser MA, Murphy B, Cannon M, Pinto H, Rosenthal DI, Gillison M, Forastiere AA: Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol; 2007 Sep 1;25(25):3971-7
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
  • This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (OP) cancer patients.
  • PATIENTS AND METHODS: Eligibility required resectable stage T2N+, or T3-T4N0-3M0 biopsy-proven squamous carcinoma, age at least 18 years, PS 0 to 2, good organ function, and no prior chemotherapy or radiation.
  • Treatment was induction paclitaxel 175 mg/m(2) and carboplatin area under the concentration-time curve (AUC) 6 for two cycles every 21 days followed by concurrent paclitaxel 30 mg/m(2) every 7 days with 70 Gy if no evidence of tumor progression.
  • RESULTS: One hundred five of 111 patients (36 larynx, 69 OP) were eligible.
  • No patient progressed while receiving chemotherapy.
  • Organ preservation was 81% at 2 years after completion of therapy (larynx 74%, OP 84%).
  • Thirteen patients required primary-site salvage surgery (seven larynx, six OP), and six of these have progressed and died (three larynx, three OP).
  • Thirteen patients developed distant metastases (seven larynx, six OP; P = .02) and 10 of 36 larynx and 11 of 69 OP patients have died as a result of their disease.
  • Two-year survival is 76% (63% larynx v 83% OP).
  • CONCLUSION: A high organ preservation rate was obtained with this regimen for OP but not for larynx patients.
  • Toxicity was low, and induction chemotherapy did not preclude delivery of concurrent chemoradiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bridged Compounds / administration & dosage. Chemotherapy, Adjuvant. Deglutition Disorders / etiology. Deglutition Disorders / prevention & control. Female. Follow-Up Studies. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pharyngectomy. Platinum / administration & dosage. Radiotherapy, Adjuvant. Recovery of Function. Salvage Therapy. Speech Disorders / etiology. Speech Disorders / prevention & control. Taxoids / administration & dosage. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane; 49DFR088MY / Platinum; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Cmelak AJ, Murphy BA, Burkey B, Douglas S, Shyr Y, Netterville J: Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck; 2007 Apr;29(4):315-24
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
  • BACKGROUND: The optimal drug schedule and sequencing of chemotherapy and radiation for organ preservation in head and neck cancer has yet to be determined.
  • We undertook a phase II trial of a taxane-based induction chemotherapy (ICT) followed by a taxane-based concurrent chemoradiation (CCR) regimen in patients with resectable stage III or IV disease to determine the feasibility, toxicity, and overall efficacy.
  • METHODS: Forty-four patients with laryngeal or tongue base carcinomas were enrolled.
  • All patients received 3 cycles of chemotherapy with paclitaxel 175 mg/m(2) and carboplatin AUC (area under the curve) 6-7.5 over 30 minutes on days 1, 22, and 43.
  • Responding patients went on to receive radiation (70 Gy/7 weeks) with cisplatin 75 mg/m(2) IV on days 1, 22, and 43 and weekly paclitaxel 30 mg/m(2) IV (n = 22).
  • RESULTS: Twenty-three patients with stage III and 21 patients with stage IV disease were enrolled.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Paclitaxel / therapeutic use. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17252600.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Yoshimura R, Kagami Y, Ito Y, Asai M, Mayahara H, Sumi M, Itami J: Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):1017-23
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy.
  • PURPOSE: To analyze the outcome in patients with early-stage hypopharyngeal cancer (HPC) who were treated with radiotherapy (RT).
  • METHODS AND MATERIALS: Between February 1988 and February 2007, 77 patients with Stage I or Stage II HPC underwent definitive RT in the Division of Radiation Oncology at the National Cancer Center Hospital.
  • RESULTS: The rates of overall survival, HPC-specific survival, HPC recurrence-free survival, and local control with laryngeal voice preservation for the 77 patients at 5 years were 47%, 74%, 57%, and 70%, respectively.
  • The survival rates were not affected by the patient characteristics or treatment factors, but the RT field was significantly correlated with local control in a multivariate analysis.
  • Of the 77 patients, 83% had synchronous or metachronous malignancies, but these malignancies did not influence the survival of the patients if the malignancies were detected at an early stage.
  • CONCLUSION: RT is an appropriate treatment method for early-stage HPC.
  • However, because synchronous or metachronous malignancies occur at a relatively high frequency, careful follow-up and the early detection of such malignancies are critical.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Radiotherapy Dosage. Salvage Therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19910141.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Riva C, Lavieille JP, Schmerber S, Cuisnie O, Reyt E: Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. Int J Oncol; 2000 Sep;17(3):543-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
  • The objective of this phase II prospective study was to determine the efficacy and the toxicity of a new schedule of neoadjuvant chemotherapy in locally advanced squamous cell carcinomas of the head and neck (SCCHN).
  • Thirty-three patients were included in this study (13 stage III and 20 stage IV).
  • Cisplatin (CDDP: 35 mg/m2), 5-fluorouracil (FU: 2 g/m2) and folinic acid (FA: 500 mg/m2) were administered by continuous i.v. infusion for 24 h, once every 7 days.
  • Six cycles of neoadjuvant chemotherapy were planned before definitive locoregional treatment.
  • One treatment-related death was observed after grade IV neutropenia at the fourth cycle.
  • Survival and DFS duration were significantly higher in cases of CR or in laryngeal localization.
  • Therefore, the administration of the 3 drugs by a 24 h continuous i.v. infusion reached an efficient level for drug modulation.
  • This new weekly schedule is as active as other standard therapy in the disease but significantly less toxic as neoadjuvant chemotherapy in advanced untreated SCCHN.
  • With the low toxicities observed with this schedule, additional treatment (surgery and/or radiotherapy) is warranted to evaluate the impact on overall survival of SCCHN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Chemotherapy, Adjuvant. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / pharmacokinetics. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / pharmacokinetics. Gastrointestinal Diseases / chemically induced. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / pharmacokinetics. Life Tables. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Remission Induction. Risk Factors. Stomatitis / chemically induced. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10938396.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, Biörklund A, Jannert M, Westin T, Kaasa S: A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope; 2001 Aug;111(8):1440-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data.
  • OBJECTIVES: To evaluate the health-related quality of life (HRQL) of patients with head and neck cancer during and after treatment with radiotherapy, surgery, and chemotherapy.
  • Health-related quality of life was assessed at baseline and at 1, 2, 3, 6, and 12 months after start of treatment by means of the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire and the EORTC head and neck cancer-specific questionnaire.
  • Three hundred fifty-seven patients with cancer in the oral cavity, pharynx, larynx, nose, sinuses, and salivary glands and neck node metastases from unknown primaries filled in the questionnaires at baseline.
  • The general trend was that HRQL deteriorated significantly during treatment, followed by a slow recovery until the 12-month follow-up with few exceptions (senses, dry mouth, and sexuality).
  • The patients with pharyngeal cancer in general reported worse HRQL compared with the other groups and did not reach pretreatment values in several domains.
  • Stage was also an important factor for HRQL in patients with head and neck cancer.
  • CONCLUSION: Detailed knowledge about the differences between groups and changes over time may aid us in the communication with patients and in the design of intervention studies focusing on improvement of the support and rehabilitation of patients with head and neck cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngeal Neoplasms. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms. Pharyngeal Neoplasms. Prospective Studies

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568582.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Nakamura T, Kodaira T, Tachibana H, Tomita N, Yokouchi J, Fuwa N: Clinical outcome of oropharyngeal carcinoma treated with platinum-based chemoradiotherapy. Oral Oncol; 2009 Sep;45(9):830-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of oropharyngeal carcinoma treated with platinum-based chemoradiotherapy.
  • To determine the efficacy, feasibility, and toxicity of treated with platinum-based chemoradiotherapy for oropharyngeal carcinoma.
  • A retrospective survey of 91 patients who underwent platinum-based chemotherapy and radiotherapy for oropharyngeal cancer at Aichi Cancer Center Hospital between 1971 and 2003.
  • Nine patients who had a tumor in the base of the tongue were also treated with arterial infusion chemotherapy.
  • At a median follow-up of 63months (range, 2-190 months), 26 (29%) patients developed recurrence.
  • Five patients (5%) developed distant metastases.
  • The 5-year overall survival was 85% for stage I-II and 62% for stage III-IV.
  • Two patients developed grade 3 (mandibular bone necrosis) or 4 (laryngeal edema) late toxicities.
  • In this study, platinum-based chemoradiotherapy provided good local control for oropharyngeal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Feasibility Studies. Female. Fluorouracil / administration & dosage. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Organoplatinum Compounds / administration & dosage. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457713.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS: Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1356-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate long-term swallowing function in oropharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT), and to identify novel dose-limiting criteria predictive for dysphagia.
  • METHODS AND MATERIALS: Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment.
  • Candidate dysphagia-associated organs at risk were retrospectively contoured into original treatment plans.
  • Stage distribution was T1 (12 patients), T2 (10), T3 (4), T4 (2), and TX (3), and N2 (24), N3 (5), and NX (2).
  • Thirteen patients (42%) received concurrent chemotherapy during IMRT.
  • Mean dose to glottic larynx for the cohort was limited to 18 Gy (range, 6-39 Gy) by matching IMRT to conventional low-neck fields.
  • CONCLUSIONS: In the context of glottic laryngeal shielding, we describe candidate oral cavity and superior pharyngeal constrictor organs at risk and dose-volume constraints associated with preserved long-term swallowing function; these constraints are currently undergoing prospective validation.
  • Strict protection of the glottic larynx via beam-split IMRT techniques promises to make chronic aspiration an uncommon outcome.

  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6 [11448365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84 [12128118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1219-30 [14630255.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1000-5 [15978743.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1813-20 [17546592.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):568-74 [18793959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Head Neck. 2009 May;31(5):611-7 [19107949.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1034-41 [14648862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1072-82 [15001247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Dysphagia. 1996 Spring;11(2):93-8 [8721066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721-30 [8948358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92 [9588921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • (PMID = 20646872.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA132281; United States / NCI NIH HHS / CA / CA132281
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS575664; NLM/ PMC4034521
  •  go-up   go-down


27. Chang MF, Wang HM, Kang CJ, Huang SF, Lin CY, Fang KH, Chen EY, Chen IH, Liao CT, Chang JT: Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan. Radiat Oncol; 2010;5:91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan.
  • PURPOSE: The aim of this study was to evaluate treatment results in our hypopharyngeal cancer patients.
  • PATIENTS AND METHODS: A total of three hundred and ninety five hypopharyngeal cancer patients received radical treatment at our hospital; 96% were male.
  • All patients received a CT scan or MRI for tumor staging before treatment.
  • The stage distribution was stage I: 2 (0.5%); stage II: 22 (5.6%); stage III: 57 (14.4%) and stage IV: 314 (79.5%).
  • Radical surgery was used first in 81 patients (20.5%), and the remaining patients (79.5%) received organ preservation-intended treatment (OPIT).
  • In the OPIT group, 46 patients received radiotherapy alone, 156 patients received chemotherapy followed by radiotherapy (CT/RT) and 112 patients received concomitant chemo-radiotherapy (CCRT).
  • RESULTS: The five-year overall survival rates for stages I/II, III and IV were 49.5%, 47.4% and 18.6%, respectively.
  • In the OPIT group, CCRT tended to preserve the larynx better (p = 0.088), with three-year larynx preservation rates of 44.8% for CCRT and 27.2% for CT/RT.
  • Thirty-seven patients developed a second malignancy, with an annual incidence of 4.6%.
  • CONCLUSIONS: There was no survival difference between OPIT and radical surgery in hypopharyngeal cancer patients at our hospital.
  • CCRT may offer better laryngeal preservation than RT alone or CT/RT.
  • Additionally, second primary cancers are another important issue for hypopharyngeal cancer management.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Incidence. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Radiotherapy. Taiwan. Tegafur / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1391-6 [20056352.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):66-74 [11291134.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61 [11298170.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2989-95 [12115388.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):733-8 [12874074.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Head Neck. 2004 Jul;26(7):561-72 [15229898.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):554-8 [15230789.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2856-64 [15254053.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):861-7 [15262764.001]
  • [Cites] Onkologie. 2004 Aug;27(4):368-75 [15347892.001]
  • [Cites] Cancer Treat Rev. 1975 Sep;2(3):177-91 [1104162.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):489-91 [911032.001]
  • [Cites] Cancer. 1983 May 15;51(10):1819-25 [6831347.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1685-91 [2317751.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):853-7 [8703389.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):142-8 [10037279.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Clin Otolaryngol. 2005 Feb;30(1):52-7 [15748191.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):279-86 [16012523.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1117-21 [16251869.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1064-71 [16505425.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 20925962.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2958972
  •  go-up   go-down


28. Barker JL Jr, Glisson BS, Garden AS, El-Naggar AK, Morrison WH, Ang KK, Chao KS, Clayman G, Rosenthal DI: Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer; 2003 Dec 1;98(11):2322-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority (13 patients) had laryngeal origin with the following American Joint Committee on Cancer stage distribution: Stage I disease in 1 patient, Stage II disease in 2 patients, Stage III disease in 6 patients, and Stage IV disease in 14 patients.
  • Nine patients underwent definitive surgery with or without postoperative radiation, and 14 patients received definitive radiotherapy.
  • The median definitive radiation dose was 66 grays (Gy) (range, 44-72 Gy) using conventional fractionation.
  • Fourteen patients received chemotherapy, with two to four cycles of induction platinum plus etoposide used most commonly.
  • RESULTS: The median follow-up time for surviving patients was 40 months (range, 15-89 months).
  • Both the 2-year OS rate (68% vs. 30%; P = 0.002) and the 2-year DFS rate (55% vs. 17%; P = 0.004) were improved with chemotherapy compared with local therapy alone.
  • Seventy-five percent of patients with measurable disease had complete clinical responses to induction chemotherapy.
  • Chemotherapy did not reduce local failure (P = 0.91).
  • The 2-year and 5-year distant metastasis rates were 54% and 71%, respectively.
  • The 2-year rates of metastases without and with chemotherapy were 79% and 39%, respectively (P = 0.006).
  • The 2-year and 5-year rates of intracranial metastases were 25% and 44%, respectively, and the 2-year and 5-year rates of isolated brain metastases were 21% and 41%, respectively.
  • CONCLUSIONS: Based on these results, the authors' treatment strategy for patients with NSNEC is sequential chemotherapy and radiation.
  • They recommend full-dose radiotherapy alone for patients with NSNEC who achieve a complete clinical response to induction chemotherapy.
  • Newer chemotherapeutic regimens or additional adjuvant chemotherapy should be investigated for patients with NSNEC given the high rate of distant failure.
  • Due to the very high rate of brain metastases among patients in the current study, the authors now consider incorporating prophylactic cranial irradiation into primary radiotherapy for individual patients who have complete clinical responses to induction chemotherapy.
  • [MeSH-major] Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Combined Modality Therapy. Cranial Irradiation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 14635065.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yoshida T, Tokashiki R, Itoh H, Nakamura K, Hiramatsu H, Tsukahara K, Shimizu S, Takada D, Okamoto I, Abe K, Suzuki M: A phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx. Jpn J Clin Oncol; 2007 Sep;37(9):641-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx.
  • BACKGROUND: We performed a phase I/II study of bi-weekly docetaxel in combination with concurrent radiotherapy to enhance the cytotoxic effect and radiosensitization and improve the rate of laryngeal preservation.
  • METHODS: Patients with T2N0-1M0, T3N0M0 hypopharyngeal cancer or T2N0-1M0, T3N0-1M0 larynx cancer were enrolled.
  • Docetaxel was administered bi-weekly (days 1, 15, 29) from the first day of radiotherapy, while 2 Gy/day of radiation was given on 5 days weekly from day 1, reaching a total of 60 Gy in 30 fractions.
  • The phase II study was conducted with docetaxel at 35 mg/m2 for 25 patients.
  • Treatment was completed without interruption in 24 patients, with a protocol implementation rate of 96%.
  • The complete response rate was 100% in laryngeal cancer, and 80% in hypopharyngeal cancer, and total (including partial response) overall response rate was 100%.
  • The laryngeal preservation rate was 96%, and the overall local control rate was 92%.
  • CONCLUSIONS: The chemoradiation therapy using bi-weekly docetaxel is an extremely effective treatment for cancer of the larynx/hypopharynx, provided that it is used for the specified stage of cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Radiation-Sensitizing Agents / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Dose Fractionation. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940076.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


30. Jo S, Juhasz A, Zhang K, Ruel C, Loera S, Wilczynski SP, Yen Y, Liu X, Ellenhorn J, Lim D, Paz B, Somlo G, Vora N, Shibata S: Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res; 2009 May;29(5):1467-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.
  • The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1alpha and VEGF expression in HPV-positive and -negative tumors.
  • PATIENTS AND METHODS: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx.
  • HIF-1alpha and VEGF expression were assessed by quantitative real-time PCR (RT-PCR).
  • There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively.
  • CONCLUSION: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Surg. 1983 Dec;12(6):418-24 [6325356.001]
  • [Cites] EMBO J. 1988 Jun;7(6):1815-20 [2458921.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):153-9 [11943893.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jul;125(1):1-9 [11458206.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):401-3 [11328843.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4611-20 [11030150.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):300-4 [10861508.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):117-23 [10585594.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2568-76 [17473185.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1418-25 [17205528.001]
  • [Cites] Cell Mol Life Sci. 2006 Apr;63(7-8):930-8 [16596339.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2558-64 [16314836.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):206-13 [15790460.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):775-82 [10213212.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):755-62 [9816227.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):145-56 [9422532.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):513-6 [9158399.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):595-604 [9028373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3187-92 [12374687.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2620-6 [12855639.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):394-400 [14506739.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):766-72 [14696105.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):468-71 [14744758.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):418-23 [15091212.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006 [15240783.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3061-9 [15284256.001]
  • (PMID = 19443352.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS431020; NLM/ PMC3582681
  •  go-up   go-down


31. Nakayama M, Hayakawa K, Okamoto M, Niibe Y, Ishiyama H, Kotani S: Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer. Jpn J Clin Oncol; 2010 Oct;40(10):921-6
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer.
  • OBJECTIVE: A Phase I/II study of S-1 combined radiation therapy was conducted in patients with Stage II (T2N0) glottic cancer.
  • The objectives in the phase II study were to estimate the local control and the overall survival, and the incidence of adverse events.
  • Radiation therapy was administered in 2-Gy daily (total 60-Gy) standard fractionation.
  • RESULTS: Seven patients were enrolled in the Phase I, and 19 in the Phase II study.
  • All 26 patients completed radiation therapy without delay.
  • One patient developed a local recurrence 28 months after the treatment.
  • CONCLUSIONS: The use of S-1 at 80 mg/m(2) per day in a split-course with 1-week rest during the course of radiation therapy was safe and effective for Stage II glottic cancer.
  • The treatment strategy employing orally available S-1 proved to be beneficial over the conventional injection of antitumor agents for maintaining the patients' quality of life.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Oxonic Acid / therapeutic use. Radiotherapy / methods. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Anemia / etiology. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Follow-Up Studies. Glottis / drug effects. Glottis / pathology. Glottis / radiation effects. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Nausea / etiology. Neutropenia / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495190.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


32. Nakamura K, Shioyama Y, Sasaki T, Ohga S, Saku M, Urashima Y, Yoshitake T, Nakashima T, Kuratomi Y, Komune S, Terashima H, Honda H: Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):680-3
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx.
  • PURPOSE: Early squamous cell carcinoma of the hypopharynx is a rare clinical entity.
  • Our objective was to analyze the outcome of patients with early hypopharyngeal cancer treated with curative radiotherapy or the combination of preoperative radiotherapy with surgery.
  • METHODS AND MATERIALS: Forty-three patients with Stage I-II hypopharyngeal cancer were initially treated with 30-40 Gy of irradiation with or without chemotherapy.
  • Thirty-two patients (74.4%) who demonstrated a complete response continued to receive further radiotherapy, with a median total dose of 61.2 Gy.
  • RESULTS: Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with Stage I disease, and in 23 (67.6%) of 34 patients with Stage II disease.
  • The disease-specific survival rates according to the T-category were 100% for patients with T1 disease and 87.2% for patients with T2 disease (p = 0.32).
  • Four patients died of hypopharyngeal cancer, and 5 died of second-primary esophageal cancer.
  • CONCLUSIONS: A majority of patients with early hypopharyngeal cancer was curable.
  • However, second malignancies influenced the overall outcome of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary. Pharyngectomy. Radiotherapy Dosage. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936545.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Nakamura K, Shioyama Y, Kawashima M, Saito Y, Nakamura N, Nakata K, Hareyama M, Takada T, Karasawa K, Watanabe T, Yorozu A, Tachibana H, Suzuki G, Hayabuchi N, Toba T, Yamada S: Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1045-50
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy.
  • PURPOSE: To analyze the outcomes of patients with early hypopharyngeal cancer treated with radical radiotherapy (RT).
  • METHODS AND MATERIALS: Ten institutions combined the data from 115 patients with Stage I-II hypopharyngeal squamous cell carcinoma treated with definitive RT between 1990 and 2001.
  • Of the 115 patients, 39 had Stage I and 76 had Stage II disease.
  • Conventional fractionation was used in 98 patients and twice-daily RT in 17 patients; chemotherapy was combined with RT in 57 patients.
  • The 5-year disease-specific survival rate by T stage was 95.8% for patients with T1 disease and 70.1% for patients with T2 disease (p=0.02).
  • Of the 115 patients, local control with laryngeal voice preservation was achieved in 34 of 39 patients with T1 lesions, including 7 patients successfully salvaged, and in 56 of 76 patients with T2 lesions.
  • Of the 115 patients, 19 died of hypopharyngeal cancer, 10 died of second primary cancers, and 14 died of other causes during the study and follow-up periods.
  • CONCLUSIONS: Patients with early hypopharyngeal cancer tended to have a good prognosis after RT.
  • However, second malignancies had an adverse effect on the overall outcomes of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Radiotherapy Dosage. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682142.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Gil Z, Fliss DM: Contemporary management of head and neck cancers. Isr Med Assoc J; 2009 May;11(5):296-300
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck cancer is the sixth most common cancer worldwide.
  • HNCs can originate in the skin or soft tissue, in the upper aerodigestive tracts (oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses, salivary glands), or in the thyroid.
  • In each of these sites, tumors vary not only by the primary site but also by pathophysiology, biological behavior, and sensitivity to radiotherapy or chemotherapy.
  • The main goals of therapy are ablation of the cancer while minimizing morbidity and preserving function and cosmesis.
  • Early-stage HNC (stage I and II) should be managed with a single modality, and advanced tumors (stage III and IV) with multimodality therapy.
  • Treatment should be directed to the primary tumor and the area of its lymphatic drainage--the neck lymph nodes.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Neck Dissection. Prognosis. Quality of Life. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637508.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Number-of-references] 29
  •  go-up   go-down


36. Leichman L, Lawrence D, Leichman CG, Nava H, Nava E, Proulx G, Clark K, Khushalani NI, Berdzik J, Greco W, Smith P, Creaven PJ, Kepner JL, Javle MM, Pendyala L: Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother; 2006 Oct;18(5):514-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.
  • With a goal of identifying relations between gene expression and response (mucosal or pathological) or survival in esophageal cancer patients (stages II to IV) receiving oxaliplatin, 5-fluorouracil (5FU) and radiation, we measured in endoscopic primary tumor biopsies from 38 patients, the expression of seven genes (gammaGCS, gammaGT, MRP-2, ERCC-1, XPA, TS and DPD) prior to treatment, 1 week following oxaliplatin alone and at the end of the combined radio-chemotherapy cycle using real time QRT-PCR.
  • A higher pretreatment level of XPA was related to shorter survival with a hazard ratio of 2.43 (90% confidence interval 1.09 to 5.43) using Cox regression modeling.
  • However, multivariate analysis with a Cox model indicated low expression of XPA or TS and combined stages II and III had a higher probability of survival (for XPA: hazard ratio 3.0 and 90% C.I. of 1.3 to 6.9, with adjustment for stage included; for TS: hazard ratio is 1.98 with 90% C.I. of 0.94 to 4.20.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / genetics. Fluorouracil / pharmacology. Organoplatinum Compounds / pharmacology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy / methods. Combined Modality Therapy. Endoscopy, Digestive System. Female. Gene Expression / drug effects. Humans. Laryngeal Mucosa / drug effects. Laryngeal Mucosa / metabolism. Male. Radiation Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127229.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16056; United States / NCI NIH HHS / CA / CA-55-0786
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Müser M, Knecht R: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol; 2001 Jun;47(6):519-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx.
  • In this open uncontrolled phase I study, nine patients with stage III and IV squamous cell carcinoma of the head and neck (SCCHN) were treated with five administrations of the humanized antiepidermal growth factor receptor monoclonal antibody EMD 72000 in three consecutive ascending dose groups.
  • Loading doses of 100 mg (group I), 200 mg (group II), and 400 mg (group III) were followed by four weekly maintenance doses of half the loading doses, i.e.
  • The most frequent study drug-related AEs were fever and a transient elevation of liver enzymes.
  • In all patients, the time to reach peak serum concentrations (tmax) was within 1-3 h of the start of each EMD 72000 infusion.
  • In conclusion, EMD 72000 was very well tolerated in patients with advanced stage SCCHN.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Carcinoma, Squamous Cell / therapy. Hypopharynx. Laryngeal Neoplasms / therapy. Pharyngeal Neoplasms / therapy. Receptor, Epidermal Growth Factor / immunology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11459205.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


38. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx].
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • The distribution of the patients according to UICC in 1997 was as follows: stage I 4, stage II 15, stage III 18, stage IV 30.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • CONCLUSIONS: Poorly differentiated carcinomas of the supraglottic larynx had characteristics of the advanced stage in terms of earlier lymph node metastasis and a relatively high rate of cervical and distant metastasis.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • For patients with T3 who need partial laryngectomy and patients with advanced N stage, the combination of surgery with radiotherapy was supposed to be a priority.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement